Scholtz & Company LLC acquired a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 21,280 shares of the life sciences company's stock, valued at approximately $2,844,000. Illumina comprises approximately 1.4% of Scholtz & Company LLC's investment portfolio, making the stock its 24th biggest holding.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ILMN. FMR LLC boosted its holdings in shares of Illumina by 127.3% during the 3rd quarter. FMR LLC now owns 767,294 shares of the life sciences company's stock worth $100,063,000 after purchasing an additional 429,723 shares during the last quarter. Captrust Financial Advisors lifted its position in Illumina by 6.5% during the third quarter. Captrust Financial Advisors now owns 8,576 shares of the life sciences company's stock worth $1,118,000 after buying an additional 524 shares in the last quarter. Edgestream Partners L.P. boosted its stake in Illumina by 27.9% during the third quarter. Edgestream Partners L.P. now owns 12,212 shares of the life sciences company's stock worth $1,593,000 after buying an additional 2,661 shares during the last quarter. Bamco Inc. NY grew its holdings in Illumina by 14.7% in the 3rd quarter. Bamco Inc. NY now owns 383,621 shares of the life sciences company's stock valued at $50,028,000 after buying an additional 49,214 shares in the last quarter. Finally, Janus Henderson Group PLC increased its stake in shares of Illumina by 40.5% in the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company's stock worth $282,735,000 after acquiring an additional 625,245 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on the stock. Stephens reissued an "overweight" rating and set a $156.00 price target on shares of Illumina in a research report on Tuesday, March 11th. Canaccord Genuity Group decreased their target price on shares of Illumina from $135.00 to $115.00 and set a "hold" rating on the stock in a report on Tuesday, March 11th. Piper Sandler raised their price target on shares of Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Royal Bank of Canada decreased their price objective on Illumina from $247.00 to $128.00 and set an "outperform" rating on the stock in a report on Wednesday, March 12th. Finally, Barclays reissued an "underweight" rating on shares of Illumina in a research note on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $140.90.
Check Out Our Latest Research Report on Illumina
Illumina Stock Down 3.0 %
ILMN stock traded down $2.26 during midday trading on Friday, hitting $74.16. The company's stock had a trading volume of 3,912,056 shares, compared to its average volume of 2,222,582. Illumina, Inc. has a 52-week low of $70.64 and a 52-week high of $156.66. The firm has a market capitalization of $11.75 billion, a P/E ratio of -9.66, a PEG ratio of 1.60 and a beta of 1.38. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The firm has a 50-day simple moving average of $96.82 and a 200-day simple moving average of $125.06.
Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, equities analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.
Illumina Company Profile
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Further Reading
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
